Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

Clinical trial NCT07552389 · RECRUITING

Trial details

NCT number: NCT07552389
Sponsor: Hanlim Pharm. Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hypertension Diabete Type 2

Start date: 2025-12-18
Primary completion: 2028-12-01
Enrollment: 228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.